Skip to main content
Volume 7, Supplement 1 - 2010

Volume 7, Supplement 1 - 2010

Table of Contents

Drug Repurposing for Drug Development in Stroke Update on Stroke Therapeutics
[Rev Neurol Dis. 2010;7(suppl 1):S3-S6 doi: 10.3909/rind7S1S0001]© 2010 MedReviews®, LLCThe development of new treatments for acute stroke has been fraught with costly and spectacularly disappointing failures. Repurposing of safe, older drugs provides a lower risk alternative. Vascular protection with candesartan is one such approach.
Repurposing an Old Drug to Improve the Use and Safety of Tissue Plasminogen Activator for Acute Ischemic Stroke: Minocycline Update on Stroke Therapeutics
There is only 1 US Food and Drug Administration–approved drug for acute ischemic stroke: tissue plasminogen activator (tPA). Due to a short time window and fear of intracerebral hemorrhage (ICH), tPA remains underutilized. There is great interest in developing combination drugs to use with tPA to improve the odds of a favorable recovery and to reduce the risk of ICH. Minocycline is a broad-spectrum antibiotic that has been found to be a neuroprotective agent in preclinical ischemic stroke models.Minocycline inhibits matrix metalloproteinase-9, a biomarker for ICH associated with tPA use. Minocycline is also an anti-inflammatory agent and inhibits poly (ADP-ribose) polymerase-1. Minocycline has been safe and well tolerated in the clinical trials conducted to date.[Rev Neurol Dis. 2010;7(suppl 1):S7-S13 doi: 10.3909/rind7S1S0002]© 2010 MedReviews®, LLC
Target Brain: Neuroprotection and Neurorestoration in Ischemic Stroke Update on Stroke Therapeutics
Many treatments for acute ischemic stroke are vessel and blood based, but brain-based therapies also hold great promise. Acute neuroprotective therapies block the molecular elaboration of injury in hypoxic environments. Prehospital trials of magnesium sulfate are demonstrating the feasibility of delivering potentially brain-protective agents in the first minutes after stroke onset. Subacute neurorestoration therapies enhance neuroplasticity and brain reorganization following stroke. The greatest clinical experience with agents that can potentiate brain repair has been gained with choline precursors. Therapies that target the brain in stroke patients will increasingly complement and enhance traditional vasotherapeutics.[Rev Neurol Dis. 2010;7(suppl 1):S14-S21 doi: 10.3909/rind7S1S0003]© 2010 MedReviews®, LLC